Penumbra, Inc. PEN
Composite 59/100; the shares have moved about 8% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 14/100 — a strong mark against it.
Balance-sheet strength ranks 94/100 — a strong point in its favour. Growth ranks 89/100 — a strong point in its favour. Quality ranks 59/100 — a slight point in its favour.
Valuation ranks 14/100 — a strong mark against it. Momentum ranks 43/100 — a slight mark against it.
What the company does Penumbra designs and markets medical devices for neurovascular and peripheral thrombectomy, including systems like the Indigo, Lightning, and CAT RX, as well as neuro embolization and access products.
Key financials Penumbra reports gross margins of 67.4%, operating margins of 10.2%, and net margins of 11.8%. ROE is 12.7%, ROA 6.7%, and ROCE 12.1%. Revenue grew 15.6% year-over-year, while EPS declined -18.0%. The balance sheet is strong with a debt/equity ratio of 0.14 and current ratio of 5.75.
Stock health The stock shows mixed momentum: -1.54% over 3 months, -10.92% over 6 months, and 40.80% over 12 months. It is -11.75% below its 52-week high, with an RSI(14) of 55.20. Sideravia scores Valuation at 11.6/100, indicating rich valuation despite high Quality (58.2) and Strength (95.9) scores.
Price vs fair value The stock trades at a PREMIUM of 76.30% versus our fair-value estimate of 75.80 and at a discount of 13.05% versus the analyst 12-month target of 361.58. - Trading at a steep premium to fair value (Simply Wall St.) - High valuation multiples (P/E 73.61, EV/EBITDA 54.84) despite strong margins - Analyst target implies 13.05% upside from current price - Valuation percentile of 11.6/100 suggests limited margin of safety
Looking forward Forward P/E of 63.29 and PEG of 3.88 reflect high growth expectations. Revenue growth of 15.6% supports premium valuation, but EPS decline (-18.0%) and rich multiples warrant caution. Strength in product portfolio and balance sheet balance growth ambitions.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.